Antibodies Fight Tuberculosis Through NLRP3 Inflammasome

Tuberculosis remains a leading infectious killer, and while T cell immunity has been studied intensively, the roles and mechanisms of antibodies against Mycobacterium tuberculosis (Mtb) are less clear. In work led by corresponding author Babak Javid, researchers probed how antibodies that bind a specific Mtb protein influence innate immune signaling and protection in animal models. They focused on antibodies directed to the Mtb phosphate transporter subunit PstS1 and asked whether those antibodies could trigger inflammatory pathways inside immune cells. Rather than acting only through the classical surface Fcγ receptors that help immune cells detect antibody-tagged microbes, the study found a surprising internal route. Immune complexes formed by Mtb and PstS1-specific monoclonal antibodies activated an intracellular multiprotein complex known as the NLRP3 inflammasome in both human and mouse macrophages. Activation of NLRP3 led to increased release of the inflammatory mediator interleukin-1β. Importantly, this inflammasome-dependent process was not a laboratory curiosity: when the researchers blocked NLRP3 pharmacologically or removed the gene genetically, early antibody-driven protection in Mtb-infected mice was lost, pointing to a central role for NLRP3 in antibody-mediated defense.

The team used immune complexes composed of Mtb and monoclonal antibodies targeting the PstS1 protein to study macrophage responses. These complexes robustly activated the NLRP3 inflammasome in human and murine macrophages, producing enhanced interleukin-1β secretion. To test whether this effect depended on cell-surface antibody receptors, the investigators used Fc-domain glycosylation mutant mAbs and macrophages from Fcγ receptor-deficient mice; inflammasome activation still occurred, demonstrating independence from Fcγ receptors. Moving from cells to animals, the researchers evaluated early antibody-mediated protection in vivo. They showed that both pharmacological inhibition of NLRP3 and genetic deletion of NLRP3 completely abolished the protective effects of PstS1-specific antibodies in Mtb-infected mice. The phenomenon was not limited to laboratory monoclonal antibodies: polyclonal sera from intravenously BCG-immunized rhesus macaques also required NLRP3 for protective efficacy. Together, these results identify a consistent requirement for NLRP3 in antibody-enhanced host responses to Mtb across different antibody sources and experimental systems.

These findings reveal a previously unrecognized mechanism by which Mtb-specific antibodies can boost host defense: antibody–microbe complexes trigger the NLRP3 inflammasome, increasing interleukin-1β release and contributing to early protection. The independence from Fcγ receptors shifts thinking about how antibodies communicate with innate immune sensors inside cells, and highlights NLRP3 as a crucial mediator of this cross-talk. For tuberculosis research, the work suggests that successful vaccines or antibody-based interventions might benefit from engaging inflammasome pathways in addition to eliciting antibody binding. Because the requirement for NLRP3 was observed with both monoclonal antibodies against PstS1 and polyclonal sera from BCG-immunized rhesus macaques, the mechanism may be relevant across different immune contexts. Translating these insights into human vaccines will require careful testing, but the study opens a new avenue: designing strategies that harness antibody-driven NLRP3 activation could complement traditional approaches and potentially improve early control of Mtb infection.